Introduction
Cholinergic innervation of the cerebral cortex, the hippocampus, amygdala, and olfactory bulb originates from the basal forebrain area, an area of the brain characterized as a network of cholinergic neurons distinguishable by four cell groups (Mesulam et al., 1983a (Mesulam et al., , 1983b . The basal forebrain is comprised of (1) the septal area which provides a projection into the hippocampus with 10% of its neurons presenting as cholinergic; (2) the diagonal band nucleus, comprised of~70% cholinergic neurons; (3) the horizontal nucleus of the diagonal band, with~1% cholinergic neurons, and finally, (4) the nucleus basalis of Meynert, comprised of~90% cholinergic neurons. The basal forebrain is associated with complex behaviors, like wakefulness (Anaclet et al., 2015) and learning (Abe et al., 1998; Grothe et al., 2016; Ray et al., 2015) depending on widespread cortical innervation originating in the basal forebrain.
Lines of evidence support the relation between the cholinergic system and depression via degeneration of Basal Forebrain Cholinergic Nuclei (BFCN). Pharmacologically, cholinergic drugs show an effect on depressive state, as centrally-acting cholinergic medications can induce depressive symptoms, while anticholinergic medications can induce antidepressant effects (Janowsky et al., 1983) . Depressed patients show a hypersensitivity to cholinergic challenge (Fritze, 1993) , particularly with Rapid Eye Movement induction (Sitaram et al., 1980) . Cholinergic abnormalities occurs in depression (Mesulam, 2004) and in-vivo molecular imaging shows decreased levels of acetylcholinesterase (AChE) in the cerebral cortex, typically interpreted as cortical cholinergic denervation due to basal forebrain/nucleus basalis atrophy (Bohnen et al., 2007) , thereby supporting the hypothesis that depression may be related to cholinergic hypofunction.
The deficits in basal forebrain signaling may be associated with abnormalities in the brain's stress response system, such that the interaction between glucocorticoids and the cholinergic transmitter system contributes to BFCN degeneration (Geerings and Gerritsen, 2017; cf, Paul et al., 2015) . Corticotropin-releasing factor (CRF), a 41 amino acid peptide, plays a key role in mediating adaptive biological and behavioral functions as part of the human stress response (Bremner et al., 1997; Ottenweller et al., 1989) , and it can be readily measured in the Cerebrospinal Fluid (CSF). CRF has also been implicated in the pathophysiology of depression (Nemeroff et al., 1984) . Accumulating evidence over the past 30 years indicates an association between CRF and MDD. Direct assessment of CRF in human central nervous system compartments has been limited to CSF and post-mortem brain examination, but CSF levels in MDD has been suggested as a diagnostic and treatment marker for MDD due to the significantly increased levels of CRF in depressed patients ' CSF (Kasckow et al., 2001; Keck and Holsboer, 2001; Owens et al., 2000) and normalization of CRF levels in conjunction with depressive symptom relief (DeBellis et al., 1993; Heuser et al., 1998 
